Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results af…

The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported ...